Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer

B. Doleschal; Hossein Taghizadeh; Theresa Lentner; JM Riedl; Jeannette Granitzer; D. Morariu; Jörn Decker; Karl Aichberger; G Webersinke; Patrick Kirchweger; Andreas Petzer; Holger Rumpold

doi:10.1016/j.esmoop.2023.102064

Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer

B. Doleschal
, Hossein Taghizadeh
, Theresa Lentner
, JM Riedl
, Jeannette Granitzer
, D. Morariu
, Jörn Decker
, Karl Aichberger
, G Webersinke
, Patrick Kirchweger
, Andreas Petzer
, Holger Rumpold

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	102064
Number of pages	7
Journal	ESMO Open
Volume	8
Issue number	6
DOIs	https://doi.org/10.1016/j.esmoop.2023.102064
Publication status	Published - Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

303 Health Sciences
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

Access to Document

10.1016/j.esmoop.2023.102064

Cite this

Doleschal, B., Taghizadeh, H., Lentner, T., Riedl, JM., Granitzer, J., Morariu, D., Decker, J., Aichberger, K., Webersinke, G., Kirchweger, P., Petzer, A., & Rumpold, H. (2023). Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer. ESMO Open, 8(6), Article 102064. https://doi.org/10.1016/j.esmoop.2023.102064

@article{8c9f592a0bde4afe978fb99e62dffac8,

title = "Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer",

author = "B. Doleschal and Hossein Taghizadeh and Theresa Lentner and JM Riedl and Jeannette Granitzer and D. Morariu and J{\"o}rn Decker and Karl Aichberger and G Webersinke and Patrick Kirchweger and Andreas Petzer and Holger Rumpold",

year = "2023",

month = nov,

doi = "10.1016/j.esmoop.2023.102064",

language = "English",

volume = "8",

journal = "ESMO Open",

issn = "2059-7029",

number = "6",

}

Doleschal, B, Taghizadeh, H, Lentner, T, Riedl, JM, Granitzer, J, Morariu, D, Decker, J, Aichberger, K, Webersinke, G, Kirchweger, P, Petzer, A & Rumpold, H 2023, 'Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer', ESMO Open, vol. 8, no. 6, 102064. https://doi.org/10.1016/j.esmoop.2023.102064

TY - JOUR

T1 - Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer

AU - Doleschal, B.

AU - Taghizadeh, Hossein

AU - Lentner, Theresa

AU - Riedl, JM

AU - Granitzer, Jeannette

AU - Morariu, D.

AU - Decker, Jörn

AU - Aichberger, Karl

AU - Webersinke, G

AU - Kirchweger, Patrick

AU - Petzer, Andreas

AU - Rumpold, Holger

PY - 2023/11

Y1 - 2023/11

UR - https://www.scopus.com/pages/publications/85178925883

U2 - 10.1016/j.esmoop.2023.102064

DO - 10.1016/j.esmoop.2023.102064

M3 - Article

C2 - 37977001

SN - 2059-7029

VL - 8

JO - ESMO Open

JF - ESMO Open

IS - 6

M1 - 102064

ER -

Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer

UN SDGs

Fields of science

Access to Document

Other files and links

Cite this